• Explore /
  • Poster
  • / Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results.

Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results.

Abstract Poster

Authors

Anwaar Saeed

Anwaar Saeed

Kansas University Cancer Center, Kansas City, KS

Anwaar Saeed , Robin Park , Junqiang Dai , Raed Moh'd Taiseer Al-Rajabi , Anup Kasi , Azhar Saeed , Zachary Collins , Kayra Thompson , Lori Barbosa , Kelly Mulvaney , Vanna Manirad , Milind Phadnis , Stephen K. Williamson , Joaquina Celebre Baranda , Weijing Sun

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03539822

DOI

10.1200/JCO.2022.40.4_suppl.135

Abstract #

135

Poster Bd #

G2

Abstract Disclosures

Similar Posters

First Author: Sheng Li

First Author: David Tougeron

Poster

2023 ASCO Annual Meeting

Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.

Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.

First Author: William Joseph Chapin

First Author: Tae-Yong Kim